VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Update

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 254,125 shares, a decrease of 34.7% from the May 31st total of 389,005 shares. Approximately 3.2% of the company’s stock are sold short. Based on an average daily trading volume, of 424,498 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in VolitionRX during the third quarter worth approximately $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of VolitionRX in the second quarter valued at approximately $52,000. Jane Street Group LLC acquired a new position in shares of VolitionRX in the fourth quarter valued at approximately $28,000. Squarepoint Ops LLC bought a new position in shares of VolitionRX during the fourth quarter worth approximately $34,000. Finally, Citadel Advisors LLC increased its stake in shares of VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares during the period. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRX Price Performance

Shares of VolitionRX stock opened at $1.40 on Friday. The business has a fifty day simple moving average of $2.05 and a two-hundred day simple moving average of $3.71. VolitionRX has a 1 year low of $1.17 and a 1 year high of $16.00. The company has a market capitalization of $12.08 million, a price-to-earnings ratio of -0.34 and a beta of 1.12.

VolitionRX (NYSEAMERICAN:VNRX) last released its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The business had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.52 million. As a group, equities analysts anticipate that VolitionRX will post -2.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VNRX has been the topic of several analyst reports. Maxim Group reaffirmed a “buy” rating and set a $4.00 price target on shares of VolitionRX in a research report on Thursday, June 18th. HC Wainwright decreased their price objective on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Citigroup lowered shares of VolitionRX to a “hold” rating in a research note on Monday, April 20th. D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. Finally, Benchmark reiterated a “hold” rating on shares of VolitionRX in a research note on Tuesday, June 2nd. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.00.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.